Q1 2025 Earnings Call Transcript April 24, 2025 NovoCure Limited beats earnings expectations. Reported EPS is $-0.31, ...

Toripalimab is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, and to induce PD-1 receptor internalization (endocytosis ...

A novel combination therapy offers better outcomes for patients with KRAS G12C metastatic colorectal cancer that have stopped ...

Discover NovoCure's Q1 2025 earnings insights, including Optune Lua's NSCLC progress, global market growth, and strong revenue performance.

Researchers reveal a strategy that helps medulloblastoma, the most prevalent malignant brain tumor in children, spread and grow on the leptomeninges, the membranes surrounding the brain and spinal ...

Optune Lua received a CE Mark for metastatic non–small cell lung cancer with immune checkpoint inhibitors or docetaxel.

Data suggest that taletrectinib “provides clinically meaningful tumor shrinkage and prolonged disease control as a treatment option for advanced ROS1+ NSCLC, regardless of treatment history,” ...

The data from the Phase III LUNAR trial, which assessed the device’s treatment efficacy and safety, supported the approval.

The regulatory approval in the EU comes approximately six months after Novocure secured FDA approval of the system.

Patients who continued to receive pembrolizumab-based therapy after disease progression had longer overall survival than patients who stopped receiving pembrolizumab-based therapy.

Novocure (NASDAQ: NVCR) announced today that Optune Lua® has received a CE (Conformité Européenne) Mark for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) ...

Shares of Iovance Biotherapeutics have plummeted post-Amtagvi approval. Read more to see a full investment analysis for IOVA ...